大脑瘤性脱髓化病变:临床谱,长期结果和治疗方法
Özgü Kizek1, Ahmed Serkan Emekli2, Tuncay Gündüz2
1Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey. ozgukizek@gmail.com.
Acta neurologica Belgica
|August 11, 2025
概括
瘤性脱髓化病变 (TDLs),通常模仿瘤,通常与多发性硬化症 (MS) 相关. 尽管TDL看起来像是TDL,但长期的结果通常是有利的,特别是如果及时治疗.
科学领域:
- 神经免疫学 神经免疫学
- 放射学 放射学是一门学科.
- 神经学 神经学
背景情况:
- 瘤性脱髓化病变 (TDLs) 是一种罕见的,类似于瘤的,在中枢神经系统内的炎症性病变.
- 它们可以发生在多发性硬化症 (MS) 或其他神经炎症疾病中,占MS病例的很小比例.
- 关于TDLs的临床过程和治疗的数据有限.
研究的目的:
- 评估TDLs患者的临床过程和长期结果.
- 分析TDLs的人口,临床和放射性特征.
- 评估不同疾病修饰疗法对TDL患者的影响.
主要方法:
- 在40年的时间里 (1981-2021年) 对41名TDL患者的回顾性评估.
- 收集的数据包括人口统计,临床表现,放射学发现,疾病过程和治疗史.
- 统计分析根据疾病过程和治疗方式对结果进行了比较.
主要成果:
- 队列 (70.7%的临床隔离综合征,29.3%的MS) 具有女性占主导地位 (2.7:1) 和中位数发病年龄为25岁.
- 复发性疗程 (78%) 比单相疗程 (20%) 更常见;儿科发病与更长的疾病持续时间有关.
- 在48.8%的患者中使用了高效疗法,长期结果普遍有利 (最终EDSS 2.0的中位数).
结论:
- TDLs是神经炎症疾病中的放射性表型,最常与MS相关.
- 尽管涉及成像,但TDL通常具有有利的长期临床结果.
- 诊断的澄清 (例如,MOG IgG,抗水素-4 IgG) 和及时启动疾病修饰疗法至关重要.
相关概念视频
Long-term Depression
2.6K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
Calcium Ion Concentration Mechanism
If over...
2.6K
Alzheimer's Disease: Overview
668
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
668
Parkinson's Disease: Overview
704
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
704
Alzheimer's Disease: Treatment
261
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
261


